HC Wainwright assumed coverage on shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) in a research note issued to investors on Monday morning. The brokerage issued a buy rating and a $18.00 price target on the biotechnology company’s stock.
Separately, Stifel Nicolaus started coverage on shares of Aldeyra Therapeutics in a research report on Friday, July 1st. They set a buy rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Aldeyra Therapeutics presently has a consensus rating of Buy and an average price target of $13.96.
Aldeyra Therapeutics (NASDAQ:ALDX) traded up 1.69% during midday trading on Monday, hitting $7.83. The stock had a trading volume of 1,767 shares. Aldeyra Therapeutics has a 1-year low of $3.39 and a 1-year high of $8.19. The company has a 50-day moving average of $5.98 and a 200-day moving average of $5.65. The stock’s market cap is $48.90 million.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Wednesday, August 10th. The biotechnology company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.03. Equities research analysts forecast that Aldeyra Therapeutics will post ($1.69) EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its position in Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock worth $11,041,000 after buying an additional 700,000 shares during the period. FMR LLC boosted its position in Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock worth $10,230,000 after buying an additional 360,000 shares during the period. AWM Investment Company Inc. bought a new position in Aldeyra Therapeutics during the second quarter worth about $5,222,000. Boxer Capital LLC boosted its position in Aldeyra Therapeutics by 361.2% in the second quarter. Boxer Capital LLC now owns 291,230 shares of the biotechnology company’s stock worth $1,657,000 after buying an additional 228,084 shares during the period. Finally, Vanguard Group Inc. boosted its position in Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock worth $712,000 after buying an additional 3,718 shares during the period.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.